Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

29 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Extent of thyroidectomy and paratracheal lymph node dissection in total pharyngolaryngectomy for pyriform sinus cancer, and recurrence, survival, and postoperative hypoparathyroidism: A multicenter retrospective study.
Ariizumi Y, Hanai N, Asakage T, Seto A, Tomioka T, Miyabe J, Kessoku H, Mukaigawa T, Omura G, Teshima M, Nishikawa D, Saito Y, Asada Y, Fujisawa T, Makino T, Nishino H, Sano D, Nakahira M, Tokashiki K, Uemura H, Ueda T, Sakai A, Masuda M, Tsujikawa T, Hiei Y, Nishio N, Matsui H, Kiyota N, Homma A. Ariizumi Y, et al. Among authors: tokashiki k. Head Neck. 2024 Feb;46(2):269-281. doi: 10.1002/hed.27572. Epub 2023 Nov 13. Head Neck. 2024. PMID: 37955187
Real-world treatment patterns and outcomes in Japanese patients with cervical esophageal cancer.
Ohno K, Nasu M, Matsui H, Baba Y, Yasuda T, Sakuma J, Ikeda K, Maruo T, Okuda T, Narita N, Kato H, Kawasaki T, Sato H, Tokashiki K, Akisada N, Ishinaga H, Akashi K, Okami K, Murayama K, Yamamoto S, Kumakura Y, Kawada K, Shiotani A, Asakage T. Ohno K, et al. Among authors: tokashiki k. Esophagus. 2022 Oct;19(4):576-585. doi: 10.1007/s10388-022-00921-w. Epub 2022 May 7. Esophagus. 2022. PMID: 35525856
Real-World, Long-Term Outcomes of Nivolumab Therapy for Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck and Impact of the Magnitude of Best Overall Response: A Retrospective Multicenter Study of 88 Patients.
Matsuki T, Okamoto I, Fushimi C, Takahashi H, Okada T, Kondo T, Sato H, Ito T, Tokashiki K, Tsukahara K, Hanyu K, Masubuchi T, Tada Y, Miura K, Omura G, Sawabe M, Kawakita D, Yamashita T. Matsuki T, et al. Among authors: tokashiki k. Cancers (Basel). 2020 Nov 18;12(11):3427. doi: 10.3390/cancers12113427. Cancers (Basel). 2020. PMID: 33218183 Free PMC article.
Comparison of Dosage of Nivolumab in Efficacy and Safety for Recurrent Metastatic Squamous Cell Carcinoma.
Okada T, Fushimi C, Matsuki T, Okamoto I, Sato H, Kondo T, Tokashiki K, Kishida T, Ito T, Yamashita G, Aihara Y, Hanyu K, Kushihashi Y, Masubuchi T, Tada Y, Miura K, Harada Y, Momiyama K, Yamashita T, Omura GO, Takahashi H, Oridate N, Tsukahara K. Okada T, et al. Among authors: tokashiki k. Anticancer Res. 2022 Mar;42(3):1607-1613. doi: 10.21873/anticanres.15635. Anticancer Res. 2022. PMID: 35220258
Effects of Pembrolizumab in Recurrent/Metastatic Squamous Cell Head and Neck Carcinoma: A Multicenter Retrospective Study.
Okada T, Fushimi C, Matsuki T, Tokashiki K, Takahashi H, Okamoto I, Sato H, Kondo T, Hanyu K, Kishida T, Ito T, Yamashita G, Masubuchi T, Tada Y, Miura K, Omura GO, Yamashita T, Oridate N, Tsukahara K. Okada T, et al. Among authors: tokashiki k. Anticancer Res. 2023 Jun;43(6):2717-2724. doi: 10.21873/anticanres.16438. Anticancer Res. 2023. PMID: 37247908
29 results